Q-omics provides the consensus-scored ANXA2P3 profile across patient tissues and cancer cell-line models. ANXA2P3 expression is associated with patient survival in 20 of 34 cancer types, with the highest sampling consensus in MESO. Among the 18 cancer types available for tumor–normal comparison, ANXA2P3 is differentially expressed in 8, with the highest sampling consensus in COAD. Additionally, ANXA2P3 RNA expression shows 11,524 significant gene co-expression associations, with the highest sampling consensus in LAML. Together, these results highlight MESO, COAD, and LAML as cancer lineages where ANXA2P3 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for ANXA2P3 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes ANXA2P3 survival associations across molecular data types. ANXA2P3 RNA expression shows survival associations in the most cancer types (20), followed by mutation status (6). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible ANXA2P3 RNA expression–survival associations across cancer types. High ANXA2P3 expression shows unfavorable associations in MESO, LUAD, PAAD, BRCA and UVM, but favorable associations in THCA. The MESO Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify MESO as the clearest survival context for ANXA2P3 RNA expression.
This table summarizes ANXA2P3 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 8. The strongest signals are observed in KIRC for RNA.
This table ranks reproducible tumor–normal expression differences for ANXA2P3. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. ANXA2P3 shows higher tumor expression in COAD, KIRC, HNSC, THCA, KIRP and LIHC. The COAD box plot shows higher ANXA2P3 RNA expression in tumor versus normal tissue (log2 FC = +0.787, t-test p < 0.001).
This table shows molecular features associated with ANXA2P3 in patient tissues and cancer cell lines. In patient samples, ANXA2P3 shows the broadest associations at the RNA and protein expression levels, with LAML recurring as the lineage with the largest associated feature set. In cancer cell lines, ANXA2P3 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in NCI60_ALL.
